The PurpleLab^® Resource Center

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.

This case study explores how a pharmaceutical company successfully planned and executed a Phase III clinical trial for a new oncology drug.

Authored by Lauren Kushner, Head of Healthcare at MiQ, and Ted Sweetser, VP of Advertising Partnerships and Strategy at PurpleLab. 2024 was a year of considerable change for the pharmaceutical industry. The biggest trend was undoubtedly the progression of the Inflation Reduction Act’s negotiated drug pricing, which sees CMS negotiating on pricing for a published…